---
title: Vosoritide Helped Children With Hypochondroplasia Grow Faster in a Phase 3 Trial
description: Published Phase 3 results show vosoritide helped children with hypochondroplasia grow faster, and BioMarin has asked the FDA to expand VOXZOGO's approval.
author: Darie Nani (Editor-in-Chief)
updated: 2026-09-09T15:19:03.040Z
canonical: https://richhealthmagazine.com/article/vosoritide-hypochondroplasia-phase-3-trial-fda
image: https://cdn.nanimediahouse.com/vosoritide-hypochondroplasia-growth-275836.webp
categories: Health
content_type: News
region: United States
publication: Rich Health Magazine
schema_type: Article
---

Children with hypochondroplasia who took the drug vosoritide grew faster over a year than children given a placebo, according to results from a Phase 3 trial now published in the journal NEJM Evidence. Vosoritide, sold as VOXZOGO, is already approved in the United States for children with achondroplasia, the most common form of dwarfism. Its maker, BioMarin, has asked the Food and Drug Administration to expand that approval to include hypochondroplasia, a related but milder condition that affects bone growth in the arms and legs and comes from changes in the FGFR3 gene. The FDA has not yet ruled on the request, so this is published trial data and a pending application, not an available treatment for the condition.

## Children on the Drug Grew Nearly an Inch More in a Year

The study, [CANOPY-HCH-3](https://clinicaltrials.gov/study/NCT06455059), compared children taking vosoritide against children taking a placebo and tracked how fast they grew. After 52 weeks it met its main goal: children on the drug grew faster, adding about 2.33 centimeters per year in growth velocity over those on placebo, close to an inch and a statistically significant margin. Their standing height rose by about 2.35 centimeters more than the placebo group over the same period. Children on vosoritide also showed early, not yet significant improvements in quality of life, and BioMarin says follow-up is continuing.

## The Safety Matched What the Drug Has Shown in Achondroplasia

The trial reported a safety profile consistent with what vosoritide has shown in children with achondroplasia. Most side effects were mild, and researchers reported no treatment-related serious adverse events. Greg Friberg, BioMarin's chief research and development officer, said the results provide a comprehensive picture of the impact of the drug across multiple measures of growth in children with hypochondroplasia. The company presented the findings as a late-breaking oral presentation at the European Society for Paediatric Endocrinology 2026 Annual Meeting.

For a family, the takeaway is narrow for now. Vosoritide is approved for achondroplasia, the hypochondroplasia results are newly published and encouraging on growth, and whether it can be prescribed for hypochondroplasia rests with the FDA. Hypochondroplasia has no cure, and any conversation about the drug for a child with the condition is one for the child's specialist as the application moves through review.

## FAQ

**Q: Can vosoritide increase height?**
In the CANOPY-HCH-3 trial, children with hypochondroplasia who took vosoritide grew faster over 52 weeks than those on a placebo, gaining about 2.33 centimeters more per year in growth velocity and 2.35 centimeters more in standing height. Those are published trial results in children with this specific condition, not a guarantee for any individual child.

**Q: Is VOXZOGO FDA approved?**
VOXZOGO (vosoritide) is approved by the FDA for children with achondroplasia. It is not yet approved for hypochondroplasia. BioMarin has submitted a supplemental application asking the FDA to add that use, and the agency has not yet decided.

**Q: What is hypochondroplasia?**
It is a genetic condition that affects bone growth in the arms and legs and leads to short stature. It is caused by changes in the FGFR3 gene, and there is no cure.

**Q: How is it different from achondroplasia?**
Hypochondroplasia is a milder form of achondroplasia. Both involve the FGFR3 gene, but achondroplasia is the most common and more pronounced form of dwarfism, and it is the condition VOXZOGO is currently approved to treat.